Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)Capsule Summary

• Main Authors: Gil Yosipovitch, MD (Author), Brian S. Kim, MD (Author), Shawn G. Kwatra, MD (Author), Nicholas K. Mollanazar, MD (Author), Sonja Ständer, MD (Author), Takahiro Satoh, MD, PhD (Author), Pedro Mendes-Bastos, MD (Author), Tsen-Fang Tsai, MD (Author), Elizabeth Laws, PhD (Author), Michael C. Nivens, PhD (Author), Jennifer Maloney, MD (Author), Genming Shi, PhD (Author), Ashish Bansal, MD, MBA (Author), Ariane Dubost-Brama, MD (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis. Objective: To obtain a more precise estimate of onset and magnitude of treatment effect using PRIME/PRIME2 pooled data. Methods:...